TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02930512

Intervention type: PROCEDURE
Intervention: DXA scan

Intervention type: PROCEDURE
Intervention: pQCT scan
Study: NCT04479995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Horizon Program
Description: Telehealth videoconferencing sessions and questionnaires.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Standard medical visits with additional paper or electronic booklet.
Study: NCT03619382

Intervention type: RADIATION
Intervention: Cone Beam Computed Tomography
Description: Computer tomography (CT) of the foot/ankle for determination of motion and morphology

Intervention type: RADIATION
Intervention: Radiographs
Description: Standard radiographs of the foot/ankle as part of the screening criteria
Study: NCT03861559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate nasal spray
Description: intranasal administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo nasal spray
Description: intranasal administration
Study: NCT01659008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysteda
Study: NCT03440814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCCR
Description: Once daily oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DCCR
Description: Once daily oral administration
Study: NCT00879697

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking Training
Description: The Walking Training program was performed using a treadmill. In each session, patients performed fifteen 2-min bouts of exercise followed by a 2-min rest interval, as previously described. Walking speed was set in order to induce perceived exertion of 11 to 13 and claudication pain in the last 30 seconds of each exercise bout.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength Training
Description: The strength training program consisted of 8 exercises (leg press, crunches, unilateral knee extension, seated row, unilateral knee flexion, seated bench press, calf raises on leg press, and seated back extension). In each exercise, subjects performed 3 sets of 10 repetitions with a 2-min interval between sets and exercises.
Study: NCT05040594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PavéDerm J-Fill Soft Dermal Filler
Description: Sodium Hyaluronate 20 mg with Lidocaine hydrochloride 3 mg/mL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PavéDerm J-Fill Soft Dermal Filler
Description: Sodium Hyaluronate 20 mg with Lidocaine hydrochloride 3 mg/mL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane® Lyft Lidocaine
Description: Sodium Hyaluronate 20 mg with Lidocaine hydrochloride 3 mg/mL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane® Lyft Lidocaine
Description: Sodium Hyaluronate 20 mg with Lidocaine hydrochloride 3 mg/mL
Study: NCT01217021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] MNI-558
Description: Subjects will be injected with 5mCi, not to exceed \>10% of 5mCI, of \[18F\]MNI-558, followed by PET imaging.
Study: NCT04155671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POF
Description: Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX plus PAC(ip)
Description: FOLFOX plus intraperitoneally paclitaxel
Study: NCT00301951

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Study: NCT00916266

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: Transplantations with autologous bone marrow mononuclear stem cells by selective posterior cerebral artery angiography
Study: NCT02955615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILT-101
Description: Induction phase followed by weekly administrations of ILT-101 on top of SLE background therapy.~SLE background therapy includes ...

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Induction phase followed by weekly administrations of placebo on top of SLE background therapy.~SLE background therapy includes ...
Study: NCT00650702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost-PPDS
Description: Control of IOP compared to baseline for the low dose of Latanoprost-PPDS for 4 months or until loss of efficacy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost-PPDS
Description: Control of IOP compared to baseline for the medium dose of Latanoprost-PPDS for 4 months or until loss of efficacy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost-PPDS
Description: Control of IOP compared to baseline for the high dose of Latanoprost-PPDS for 4 months or until loss of efficacy
Study: NCT01616407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4-Methylenedioxymethamphetamine
Description: 75 mg per os, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 40 mg per os, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: capsules identical to MDMA or methylphenidate but containing no active drug
Study: NCT01437397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide/Formoterol Fumarate
Description: Inhaled Aclidinium/formoterol FDC 400/12μg, twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide/Formoterol Fumarate
Description: Inhaled Aclidinium/formoterol FDC 400/6μg, twice per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aclidinium Bromide
Description: Inhaled Aclidinium 400 μg, twice per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate
Description: Inhaled Formoterol 12 μg, twice per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled dose-matched placebo, twice per day
Study: NCT00798993

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Structured Exercise program
Description: 30 minutes on an exercise bicycle during every dialysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (25-Hydroxyvitamin D)
Description: Cholecalciferol 2000U per day will be given for duration of study to all participants

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual exercise
Description: Participants randomised to this arm at 3 months will continue on their usual exercise routine for the remaining 3 months
Study: NCT01338740

Intervention type: DRUG
Intervention: Adalimumab and Infliximab
Description: Patients with moderately to severely active Crohn's disease with primary non-response or loss of response to Adalimumab switch to Infliximab.
Study: NCT03533049

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: myFAMI
Description: Patients who are assigned to the myFAMI group will also have the smartphone application downloaded onto either the family member's smartphone or a study-provided smartphone. Following discharge from the hospital, participants will use the smartphone application to answer nine daily questions regarding tracking family coping, transplant symptoms, family management of child transplant symptoms, and family-management difficulty with medication and follow-up regimen daily for the first 30 days following discharge.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myFAMI
Description: Patients who are assigned to the myFAMI group will also have the smartphone application downloaded onto either the family member's smartphone or a study-provided smartphone. Following discharge from the hospital, participants will use the smartphone application to answer nine daily questions regarding tracking family coping, transplant symptoms, family management of child transplant symptoms, and family-management difficulty with medication and follow-up regimen daily for the first 30 days following discharge.
Study: NCT00369265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 30mg twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: placebo twice daily
Study: NCT03399552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 10mg/kg delivered by IV infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: short course of SBRT after the first two doses of avelumab
Study: NCT02765516

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plant sterols
Description: 2.0g/day of plant sterols incorporated into margarine to be consumed for 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical margarine without additional plant sterols to be consumed for 28 days
Study: NCT03327662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active CTC Assessment
Description: CTC Counts used to guide treatment switch
Study: NCT02699749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-931
Description: TAK-931 oral capsules.
Study: NCT02982980

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy Guidance
Description: Pre and postoperative assessment and orientation, guidelines for lymphedema prevention and self drainage, follow-up for rehabilitation or maintenance of joint amplitude of shoulder movements and functional return.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy Guidance
Description: Pre and postoperative assessment and orientation, guidelines for lymphedema prevention and self drainage, follow-up for rehabilitation or maintenance of joint amplitude of shoulder movements and functional return.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy Muscle strengthening
Description: The exercises performed were active-free, with the aid of a stick or resistance by elastic bands and dumbbells for flexion, extension, adduction, abduction, external and internal rotation of the shoulder, and elbow flexion and extension, besides activities to enable movements Functional. The mode of execution of the exercises was isotonic, done slowly and within the joint amplitude reached by the patient, using resistance according to the muscular capacity of each patient.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy Muscle strengthening
Description: The exercises performed were active-free, with the aid of a stick or resistance by elastic bands and dumbbells for flexion, extension, adduction, abduction, external and internal rotation of the shoulder, and elbow flexion and extension, besides activities to enable movements Functional. The mode of execution of the exercises was isotonic, done slowly and within the joint amplitude reached by the patient, using resistance according to the muscular capacity of each patient.
Study: NCT03075514

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MKD
Description: Modified ketogenic diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MCT
Description: Medium chain triglyceride ketogenic diet
Study: NCT03146416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evinacumab
Description: SC or IV administration of Evinacumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evinacumab
Description: SC or IV administration of Evinacumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evinacumab
Description: SC or IV administration of Evinacumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evinacumab
Description: SC or IV administration of Evinacumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evinacumab
Description: SC or IV administration of Evinacumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study: NCT02172885

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: Mesenchymal Stem Cell Infusions
Study: NCT01734616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Old Exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Old Acute Cocoa

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Old 7 Day Cocoa
Study: NCT00335595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOXA
Description: XELOXA Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 One cycle every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOXA-A
Description: XELOXA-A Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 during 6 cycles followed by Bevacizumab until disease progression or premature drop out of study.~One cycle every 3 weeks
Study: NCT04117516

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgery
Description: Open carpal tunnel release will be performed, in the theatre, with tourniquet, under local anesthesia and sedation, through a short longitudinal volar classical approach of the hand, that allows to visualize the complete division of the ligament.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous surgery
Description: Percutaneous carpal tunnel release will be performed, ambulatory, with a percutaneous scalpel, through a short transverse volar approach, 1-2cm proximal to the wrist, under Wide Awake Local Anesthesia with No Tourniquet.
Study: NCT03755778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Subjects will receive EDP-938 once daily on Day 1 and 8 (Part 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Subjects will receive itraconazole once daily from Day 5 to Day 18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Subjects will receive rifampin once daily from Day 5 to Day 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinidine
Description: Subjects will receive quinidine once daily from Day 5 to Day 12
Study: NCT05022576

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Robotic arm assisted PSMA PET/CT guided prostate biopsy
Description: The patients were positioned prone on PET/CT table. The regional PET/CT image of the lower pelvic region were acquired for the procedure. The images were transferred to the ROBIO™ EX workstation. The ARA workstation determined the needle trajectory, depth of the lesion and angulations. The planned trajectory was appraised for its relationship with the vital organs. Strict surgical aseptic approach was followed for the procedure under local anesthesia. An 18G x 20cm coaxial system was manually introduced through the bush and pushed with the help of robotic arm through the gluteal skin entry site to the predetermined depth in the prostate. The real-time placement of the needle was confirmed with low dose CT and the biopsy specimens were retrieved. After the procedure, patient vitals and any difficulty in micturition were observed for two hours in the recovery area. The specimens were sent for histopathological examination.
Study: NCT03460249

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BP measurement
Description: the BP will be measured in the chair position followed by the table position and also in the reverse sequence

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BP measurement
Description: the BP will be measured in the chair position followed by the table position and also in the reverse sequence
Study: NCT05484752

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Peripheral Magnetic Stimulation
Description: Repetitive Peripheral Magnetic Stimulation at knee joint 1 session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Conventional exercise and life style modification

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Education
Description: Conventional exercise and life style modification
Study: NCT03450122

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC
Study: NCT00371865

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy
Description: 8 group-administered sessions of Cognitive-Behavioral Therapy; includes relaxation, cognitive restructuring, and problem-solving

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-based therapy
Description: 8 group-administered sessions of Acceptance-based therapy; includes mindfulness, values, and committed action
Study: NCT04500782

Intervention type: OTHER
Intervention: Observation at home.
Description: An appointment will be made at home, first one of the parents will be interviewed using the 'Social Functioning' subdomain of the PEDI-NL (Ostensjo, Bjorbaekmo, Brogren Carlberg, \& Vollestad, 2006) to determine the validity of the CFCS-NL and the VSS NL . This section contains some aspects that question the communication skills. The PEDI-NL was chosen as there is no gold standard to investigate functional communication in people with CP. Most standardized test and observational instruments only investigate language comprehension and / or language production and are furthermore developed for normally developing children. On the other hand, a video recording will be made in which the child interacts with a relative and an unknown person (the researcher) so that the CFCS-NL and VSS-score can be determined by the student and the speech therapists of the CP reference center.
Study: NCT01383577

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single hemorrhoidal ligation
Description: Effective ligation of one hemorrhoidal group and sham ligation of the two other major hemorrhoidal groups is performed in each of three sessions of treatment. Final revision is performed 90 days after first session of hemorrhoidal ligation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Triple hemorrhoidal ligation
Description: The three major hemorrhoidal groups are ligated in the first session of ligation. Sham triple hemorrhoidal ligations are performed 30 and 60 days after the first session. Final revision is done 90 days after first ligation session.
Study: NCT00254462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Participants will receive atomoxetine for 8 weeks up to a maximum of 1.8 mg/kg/day. Dosed once daily in capsule formulation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo for 8 weeks. Dosed once daily, capsule formulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training
Description: All children will receive parent training for the duration of the study.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Parent Training
Description: All children will receive parent training for the duration of the study.
Study: NCT02323269

Intervention type: DRUG
Intervention: dimethyl fumarate
Description: administered according to the local product label (i.e., Canadian Product Monograph).

Intervention type: DRUG
Intervention: dimethyl fumarate
Description: administered according to the local product label (i.e., Canadian Product Monograph).
Study: NCT00376870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: pioglitazone 30 mg/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 30 mg/d
Study: NCT02528903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHAB5553A
Description: Single intravenous administration, at various doses, depending on the cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHAB5553A
Description: Single intravenous administration, at various doses, depending on the cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHAB5553A
Description: Single intravenous administration, at various doses, depending on the cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHAB5553A
Description: Single intravenous administration, at various doses, depending on the cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHAB5553A
Description: Single intravenous administration, at various doses, depending on the cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Single intravenous dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Single intravenous dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Single intravenous dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Single intravenous dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Single intravenous dose
Study: NCT02270242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ticagrelor
Study: NCT02324075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior change
Description: Non governmental organization delivers communication intervention with facilitating hardware, a waste bin and bucket
Study: NCT04759976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robotic motor training
Description: The experiments consist in performing motor tasks with upper-limb robotic devices.
Study: NCT03319485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate Pallidotomy
Description: ExAblate Pallidotomy for Parkinson's Disease

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham ExAblate Pallidotomy
Description: ExAblate MRgFUS Sham Procedure